

FOI Ref: 26/123

20th February 2026

Eastbourne District General Hospital

Kings Drive
Eastbourne
East Sussex
BN21 2UD

Tel: 0300 131 4500
Website: www.esht.nhs.uk

Further to your recent request for information made under the Freedom of Information Act (FOIA) 2000, I now set out our answers to your specific questions, and any clarifications sought and provided, as follows:

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of October 2025 and the end of December 2025, or latest 3-month period available?

Name of medicine	Number patients treated
1.1 Abemaciclib (Verzenios)	50
1.2 Alpelisib (Piqray)	2
1.3 Elacestrant (Orserdu)	6
1.4 Fulvestrant (fulvestrant or Faslodex)	39
1.5 Inavolisib (Inaqovi)	0
1.6 Palbociclib (Ibrance)	32
1.7 Ribociclib (Kisqali)	99
1.8 Capivasertib (Truqap)	0
1.9 Talazoparib (Talzenna)	0
1.10 Olaparib (Lynparza)	8

Cont.../

- Q2.** How many patients received the following medicines for early breast cancer in the 3 months between the start of October 2025 and the end of December 2025, or latest 3-month period for which data are available?

Name of combination or monotherapy	Number patients treated
2.1 Abemaciclib (Verzenios)	47
2.2 Ribociclib (Kisqali)	0
2.3 Olaparib (Lynparza)	0

- Q3.** How many patients received the following medicines with curative treatment intent in the 3 months between the start of October 2025 and the end of December 2025, or latest 3-month period for which data are available?

Name of combination or monotherapy	Number patients treated
3.1 Abemaciclib (Verzenios)	8
3.2 Ribociclib (Kisqali)	20

- Q4.** How many patients were treated with the following medicines in combination with fulvestrant in the 3 months between the start of October 2025 and the end of December 2025, or latest 3-month period available?

Name of combination or monotherapy	Number patients treated
4.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)	0
4.2 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)	7
4.3 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)	26

- Q5.** How many patients were treated specifically for breast cancer in the 3 months between the start of October 2025 and the end of December 2025?

Type of breast cancer	Number patients treated
5.1 Olaparib - All types of breast cancer	0
5.2 Olaparib - Locally advanced or metastatic breast cancer	0
5.3 Talazoparib – All types of breast cancer	0

- Q6. How many patients were treated in total with the following products in the 3 months between 1st October 2025 to the end of December 2025, or latest 3-months for which data are available?

Name of medicine	Number patients treated
6.1 Pertuzumab (Perjeta)	1
6.2 Pertuzumab with Trastuzumab (Phesgo)	41
6.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab)	44
6.4 Trastuzumab Deruxtecan (EnHertu)	2
6.5 Trastuzumab Emtansine (Kadcyla)	13
6.6 Tucatinib (Tukysa)	1
6.7 Neratinib (Nerlynx)	0

- Q7. How many patients were treated with the following products for a diagnosis of Breast Cancer (ICD-10 codes = C50*, D509) in the 3 months between 1st October 2025 to the end of December 2025, or latest 3-months for which data are available?

Name of medicine	Number patients treated
7.1 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab)	42
7.2 Trastuzumab Deruxtecan (EnHertu)	2

- Q8. How many patients received the following products with curative treatment intent in the 3 months between the start of October 2025 to the end of December 2025, or latest 3-month period for which data are available?

Products	Number patients treated
8.1 Pertuzumab (Perjeta)	1
8.2 Pertuzumab with Trastuzumab (Phesgo)	11
8.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, Trastuzumab)	19
8.4 Trastuzumab Emtansine (Kadcyla)	6

Q9. How many patients received the following products as part of neoadjuvant or adjuvant therapy in the 3 months between the start of October 2025 to the end of December 2025, or latest 3-month period for which data are available?

Products	Neoadjuvant	Adjuvant	Total Neo-adj or adjuvant
9.1 Pertuzumab (Perjeta)	0	1	1
9.2 Pertuzumab with Trastuzumab (Phesgo)	13	19	32
9.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab)	16	7	23
9.4 Trastuzumab Emtansine (Kadcyla)	8	5	13

Q10. How many patients received trastuzumab deruxtecan (Enhertu) for the following types of breast cancer in the 3 months between the start of October 2025 to the end of December 2025, or latest 3-month period for which data are available?

Treatment intent	Number patients treated
10.1 HER2+ve Breast Cancer	2
10.2 HER2-low Breast Cancer	0

I trust this information is helpful in its detail or explanation however, if you are dissatisfied with the response, then you have the right to request an internal review. If you wish to seek an internal review, please write to the Freedom of Information Team at esh-tr.foi@nhs.net quoting the above FOI reference number, within 40 working days. Please note the Trust is not obliged to accept a request for an internal review after this time period.

Yours faithfully

Freedom of Information (FOI) Team
East Sussex Healthcare NHS Trust
0300 131 4716
Core Hours of Business: Monday to Friday 9.00am to 4.00pm